Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial
Christopher Grunseich, Ram Miller, Therese Swan, David J. Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew N. Meriggioli, Angela Kokkinis, Robert D. Guber, Maher S. Budron, John Vissing, Gianni Soraru, Tahseen Mozaffar, Albert Ludolph, John T. Kissel, Kenneth H. Fischbeck, Christopher GrunseichRam Miller, Therese Swan, David J. Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew N. Meriggioli, Julia Dahlqvist, Nanna Witting, John Vissing, Ilaria Martinelli, Giorgia Querin, Gianni Soraru, Namita A. Goyal, Tiyonnoh M. Cash, Brian Minton, Tahseen Mozaffar, Angela Rosenbohm, Ulrike Weiland, Patrick Weydt, Albert Ludolph, Sharon Chelnick, Stanley Iyadurai, Wendy King, John T. Kissel, Maher S. Budron, Robert D. Guber, Angela Kokkinis
Dive into the research topics of 'Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial'. Together they form a unique fingerprint.